SIVE#85
Thesis
Q1 pipeline +77% is key metric. Current losses from sales expansion for US listing prep. CPO TAM expanding to $91B. Ignore near-term financials.
By @ParadisLabs · View post ↗
Original post text
$SIVE Q1 Earnings: Revenue: $6.7M (-22% YoY) EBITDA: -$1.5M EPS: $0.32 (-25%) Pipeline: +77% - KEY NUMBER Ignore the financials - losses are from expanding sales team to support the pipeline + preparations for U.S. listing. Upcoming exponential CPO TAM expansion to $91B https://t.co/k9NaiiuBYZ
🐂 Bull Case
- CPO TAM expanding to $91B creates massive addressable market for early mover
- US listing preparation signals management confidence and will unlock US institutional capital
- Pipeline +77% is the leading indicator for revenue acceleration in qualification-cycle business
🐻 Bear Case
- Current financials are deteriorating (-22% revenue, negative EBITDA) - thesis entirely forward-looking
- US listing execution risk - dilution, compliance costs, market timing
- CPO technology may face competing approaches that slow adoption timeline
🚫 Invalidation
Close below SEK 11 (SMA200) on above-average volume
Break Conditions
- Revenue does not inflect positive within 2 quarters
- US listing delayed beyond Q4 2026
Price Tracking
| Label | Ticker | Price | Recorded |
|---|---|---|---|
| t+3d | SIVE | $68.95 | 2026-05-29 18:36:58 |
| t+3d | SIVE | $78.80 | 2026-06-05 18:36:00 |
Metadata
T0 Price: $68.95
Created: 2026-05-29 18:34:35
Scored: 2026-05-29T18:36:07.442324+00:00
Updated: 2026-06-05T18:36:00.779952+00:00